YCMGA
AUTL

York Capital Management Global Advisors’s Autolus Therapeutics AUTL Stock Holding History

York Capital Management Global Advisors’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-24,200
Closed -$390K – 50
2019
Q2 		$390K Buy
+24,200
New +$541K 0.02% 52

Other funds holding AUTL

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

York Capital Management Global Advisors's AUTL Position: Q3 2019 in Review

York Capital Management Global Advisors sold out of Autolus Therapeutics (AUTL) in Q3 2019, closing a stake of 24,200 shares — an estimated $390K sold.

York Capital Management Global Advisors first reported a position in AUTL in Q2 2019 and held it in 1 quarter. The position peaked at $390K in Q2 2019. 43 funds tracked by Wall St. Rank hold AUTL as of Q3 2019.

  • York Capital Management Global Advisors reported no remaining Autolus Therapeutics position as of Q3 2019 after selling out during the quarter.
  • York Capital Management Global Advisors sold 24,200 Autolus Therapeutics shares in Q3 2019, an estimated $390K.
  • York Capital Management Global Advisors first reported a position in Autolus Therapeutics in Q2 2019 and held it in 1 quarter.
  • York Capital Management Global Advisors's Autolus Therapeutics position peaked at $390K in Q2 2019.
  • 43 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2019.

Based on York Capital Management Global Advisors's 13F filing for Q3 2019, filed 15 Nov 2019.